Lack Of Diversity In Clinical Trials Presents Possible Health Consequences
By Rae Ellen Bichell,
National Public Radio
| 12. 17. 2015
Untitled Document
Despite striking ethnic disparities in the incidence and mortality of diseases like cancer and respiratory disease, minorities are not well represented in clinical trials. A paper out in the journal PLOS Medicine says two main barriers to achieving diverse clinical trials are the expense of recruiting minority subjects, and fears of exploitation in medical research.
ARI SHAPIRO, HOST:
About 40 percent of Americans belong to a racial or ethnic minority. But the people who participate in clinical trials are much more homogeneous. These trials are the studies that test whether drugs work and inform doctors' decisions about how to treat their patients. As NPR's Rae Ellen Bichell reports, that mismatch can have big health consequences.
RAE ELLEN BICHELL, BYLINE: Here's the gist of an article this week in the journal PLOS Medicine - clinical trials in biomedical research are too white.
SAM OH: Yeesh (laughter) it's a little jarring to hear it that way.
BICHELL: But that's the reality. Sam Oh is an epidemiologist at UC San Francisco. He was one of a group of 14 researchers who...
Related Articles
By Lars Cornelissen, The Conversation | 11.28.2025
Prime Minister Keir Starmer thinks that racism is returning to British society. He has accused Nigel Farage’s Reform UK of sowing “toxic division” with its “racist rhetoric”.
Starmer’s comments follow a trend that has seen senior Labour party officials portray...
By Grace Won, KQED Forum [with CGS' Katie Hasson] | 12.02.2025
In the U.S., it’s illegal to edit genes in human embryos with the intention of creating a genetically engineered baby. But according to the Wall Street Journal, Bay Area startups are focused on just that. It wouldn’t be the first...
By Emma Cieslik, Ms. Magazine | 11.20.2025
Several recent Biopolitical Times posts (1, 2, 3, 4) have called attention to the alarmingly rapid commercialization of “designer baby” technologies: polygenic embryo screening (especially its use to purportedly screen for traits like intelligence), in vitro gametogenesis (lab-made eggs and sperm), and heritable genome editing (also termed embryo editing or reproductive gene editing). Those three, together with artificial wombs, have been dubbed the “Gattaca stack” by Brian Armstrong, CEO of the cryptocurrency company...
